Ondine Biomedical Inc 66.7% potential upside indicated by RBC Capital Markets

Ondine Biomedical Inc with ticker (LON:OBI) now has a potential upside of 66.7% according to RBC Capital Markets.



RBC Capital Markets set a target price of 60 GBX for the company, which when compared to the Ondine Biomedical Inc share price of 20 GBX at opening today (03/02/2023) indicates a potential upside of 66.7%. Trading has ranged between 15 (52 week low) and 55 (52 week high) with an average of 103,776 shares exchanging hands daily. The market capitalisation at the time of writing is £38,756,284.

Ondine Biomedical Inc. is a Canada-based biotechnology company. The Company is engaged in the development and commercialization of anti-infective therapies covering a various bacterial, fungal and viral infections primarily using antimicrobial photodynamic therapy (aPDT) as a platform technology for its products, which are used as an alternative to the use of antibiotics. The Company’s aPDT products uses laser-based activation of compounds to treat a range of medical infections. Its Photodisinfection platform, is a light-based antimicrobial technology that provides rapid destruction of a range of pathogens without causing antibiotic resistance. The Company offers Steriwave product, which is a photodisinfection-based medical device to eliminate harmful nasal pathogens that can lead to healthcare-associated infections (HAIs).